Login
$COGT
$27.15 -$0.29 (1.06%) After hours

$COGT 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026

02 Sep 2026 8-K: Entry into a Material Definitive Agreement

On September 1, 2026, Cogent Biosciences, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Agreement”) with Hovione FarmaCiencia S.A. (“Hovione”) to manufacture bezuclastinib spray-dried dispersion and bezuclastinib ...

10 Aug 2026 8-K: Other Events

We have examined the Registration Statement on Form S-3 (the “Registration Statement”) of Cogent Biosciences, Inc., a Delaware corporation (the “Company”), filed with the Securities and Exchange Commission (the “Commission”) pursuant to ...

10 Aug 2026 8-K: Results of Operations and Financial Condition

On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

At the Annual Meeting, each of the Company’s director nominees was elected and each of the other proposals voted on were approved. The final voting results are set forth below.

05 May 2026 8-K: Results of Operations and Financial Condition

Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST)

17 Feb 2026 8-K: Results of Operations and Financial Condition

SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026

08 Dec 2025 8-K: Other Events

On December 6, 2025 and December 8, 2025, Cogent Biosciences, Inc. (the “Company”) presented the full results from its SUMMIT clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis (“NonAdvSM”) and announced p...

18 Nov 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

We have acted as counsel to Cogent Biosciences, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) of a Registration Statement on For...

13 Nov 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Cogent Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Jefferies LLC and J.P. Morgan Securities LLC are acting as...

10 Nov 2025 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Peak Trial: Bezuclastinib + Sunitinib in Gastrointestinal Stromal Tumors (GIST) Top-Line Results Investor Webcast November 10, 2025

03 Nov 2025 8-K: Results of Operations and Financial Condition

Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December

11 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

THIS INSTRUMENT IS AN INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in the building known as 180 CityPoint and having an address at 180 Third Avenue, Waltham, Massac...

05 Aug 2025 8-K: Results of Operations and Financial Condition

Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints

10 Jul 2025 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition

Cogent Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC, Leerink Partners LLC and Gugge...

07 Jul 2025 8-K: Other Events

On July 7, 2025, Cogent Biosciences, Inc. (the “Company”) announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis (“NonAd...

11 Jun 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

Facility provides additional funding for next steps of the Company’s growth, including the expected launch of bezuclastinib in 2026

05 Jun 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders +1 more

Cogent Biosciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that:

06 May 2025 8-K: Results of Operations and Financial Condition

Three Registration-Directed Top-line Data Readouts Remain on Track in 2025:

25 Feb 2025 8-K: Results of Operations and Financial Condition

Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support